相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression
Lei Li et al.
CELL DEATH & DISEASE (2021)
Tribulus terrestris fruit extract inhibits autophagic flux to diminish cell proliferation and metastatic characteristics of oral cancer cells
Chih-Wen Shu et al.
ENVIRONMENTAL TOXICOLOGY (2021)
Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients
Marta Sanz-Alvarez et al.
CANCERS (2021)
Detection of Autophagy-Related Gene Expression by Conjunctival Impression Cytology in Age-Related Macular Degeneration
Chih-Wen Shu et al.
DIAGNOSTICS (2021)
Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer
Vanessa J. Kelly et al.
THERANOSTICS (2020)
Oxidative stress-modulating drugs have preferential anticancer effects - involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism, and migration
Jen-Yang Tang et al.
SEMINARS IN CANCER BIOLOGY (2019)
Targeting the PI3-kinase pathway in triple-negative breast cancer
J. Pascual et al.
ANNALS OF ONCOLOGY (2019)
The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells
Jin-Shiung Cheng et al.
FRONTIERS IN ONCOLOGY (2019)
Kinome-Wide Screening with Small Interfering RNA Identified Polo-like Kinase 1 as a Key Regulator of Proliferation in Oral Cancer Cells
Yih-Gang Goan et al.
CANCERS (2019)
Association of ATG4B and Phosphorylated ATG4B Proteins with Tumorigenesis and Prognosis in Oral Squamous Cell Carcinoma
Pei-Feng Liu et al.
CANCERS (2019)
A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy
Walter Becker
FEBS JOURNAL (2018)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Jingru Zhang et al.
BLOOD CANCER JOURNAL (2018)
Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses Autophagy and Sensitizes Cancer Cells to Chemotherapy
Pei-Feng Liu et al.
THERANOSTICS (2018)
Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
Yen-Dun Tony Tzeng et al.
FRONTIERS IN PHARMACOLOGY (2018)
Map1lc3b and Sqstm1 Modulated Autophagy for Tumorigenesis and Prognosis in Certain Subsites of Oral Squamous Cell Carcinoma
Pei-Feng Liu et al.
JOURNAL OF CLINICAL MEDICINE (2018)
The role of the Hedgehog signaling pathway in cancer: A comprehensive review
Ana Marija Skoda et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES (2018)
Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells
Hua Chen et al.
Oncotarget (2017)
Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping
Xiaofeng Dai et al.
JOURNAL OF CANCER (2017)
High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer
Steven P. Williams et al.
SCIENTIFIC DATA (2017)
Ablation of ATG4B Suppressed Autophagy and Activated AMPK for Cell Cycle Arrest in Cancer Cells
Pei-Feng Liu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Trastuzumab and survival of patients with metastatic breast cancer
Karin Kast et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2017)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance
Wolfgang Gruber et al.
ONCOTARGET (2016)
Triple-negative breast cancer: treatment challenges and solutions
Joelle Collignon et al.
BREAST CANCER-TARGETS AND THERAPY (2016)
A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr286, not Thr288
Anne L. Ashford et al.
BIOCHEMICAL JOURNAL (2014)
MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis
S-H Chan et al.
ONCOGENE (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control
Walter Becker
CELL CYCLE (2012)
Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice
Tomoko Masuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Yelena Y. Janjigian et al.
CLINICAL CANCER RESEARCH (2011)
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
Jingchun Gao et al.
CANCER BIOLOGY & THERAPY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma
XB Deng et al.
CANCER RESEARCH (2006)
分享论文
